- Reports /
- Poultry Feed Premix Market
Poultry Feed Premix Market
Poultry Feed Premix Market Market Research Report – Segmented By Ingredient (Antibiotics, Vitamins, Antioxidants, Amino Acids, Minerals, Other Ingredients) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Ingredient
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Poultry Feed Premix Market was valued at US $26.00 billion in 2021 and is projected to grow at 6.99% CAGR over the forecast period to reach US $39.00 billion by 2027. Poultry Feed Premix Market represented US $3.29 billion opportunity over 2019-2021 and estimated to create US $13.01 billion opportunity in 2027 over 2021.
Poultry Feed Premix from Consainsights analyses the Poultry Feed Premix Market in the Life Sciences industry over the forecast period to 2027.
Poultry Feed Premix research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Poultry Feed Premix segmentation includes Ingredient and Geography.
Based on the Ingredient, the Poultry Feed Premix analysis covers Antibiotics, Vitamins, Antioxidants, Amino Acids, Minerals, Other Ingredients.
In Ingredient segment, Antibiotics segment has highest cagr growth of 6.19%.
Based on the region, the Poultry Feed Premix analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include Cargill Inc., Land O' Lakes Inc., DBN Group, Archer Daniels Midland Company, ForFarmers NV, DLG Group, DSM Animal Nutrition, De Heus Animal Nutrition BV, Lallemand Inc., Biomin GmbH, Kent Nutrition Group Inc., InVivo NSA, Continental Grain Company, BEC Feed Solutions, Nutreco NV and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Ingredient
Introduction
In 2021, Antibiotics segment has the highest revenue of US $11.24 billion and is expected to grow at CAGR of 6.19% by 2027 Antibiotics segment has highest cagr growth of 6.19%.
Antibiotics
Antibiotics segment was valued at US $9.82 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $16.87 billion by 2027. Antibiotics segment represented US $1.42 billion opportunity over 2019-2021 and estimated to create US $5.62 billion opportunity in 2027 over 2021.
Vitamins
Vitamins segment was valued at US $5.97 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $10.25 billion by 2027. Vitamins segment represented US $0.86 billion opportunity over 2019-2021 and estimated to create US $3.42 billion opportunity in 2027 over 2021.
Antioxidants
Antioxidants segment was valued at US $3.00 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $5.16 billion by 2027. Antioxidants segment represented US $0.43 billion opportunity over 2019-2021 and estimated to create US $1.72 billion opportunity in 2027 over 2021.
Amino Acids
Amino Acids segment was valued at US $2.21 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $3.80 billion by 2027. Amino Acids segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.27 billion opportunity in 2027 over 2021.
Minerals
Minerals segment was valued at US $1.33 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $2.28 billion by 2027. Minerals segment represented US $0.19 billion opportunity over 2019-2021 and estimated to create US $0.76 billion opportunity in 2027 over 2021.
Other Ingredients
Other Ingredients segment was valued at US $0.38 billion in 2019 and is projected to grow at 6.19% CAGR over the forecast period to reach US $0.65 billion by 2027. Other Ingredients segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.22 billion opportunity in 2027 over 2021.